Conduit Pharmaceuticals Inc. (NASDAQ:CDT – Get Free Report) Director Andrew Regan sold 1,514,100 shares of the business’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $0.26, for a total value of $393,666.00. Following the sale, the director now owns 177,627 shares in the company, valued at $46,183.02. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Andrew Regan also recently made the following trade(s):
- On Monday, July 15th, Andrew Regan sold 1,005,200 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.25, for a total value of $251,300.00.
- On Friday, July 12th, Andrew Regan sold 1,389,820 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.25, for a total transaction of $347,455.00.
- On Wednesday, July 10th, Andrew Regan sold 150,000 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.33, for a total transaction of $49,500.00.
- On Monday, July 8th, Andrew Regan sold 35,923 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.51, for a total transaction of $18,320.73.
- On Wednesday, July 3rd, Andrew Regan sold 1,000 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.64, for a total transaction of $640.00.
Conduit Pharmaceuticals Price Performance
Shares of NASDAQ CDT opened at $0.14 on Friday. The business has a 50-day moving average of $0.17 and a 200-day moving average of $1.77. Conduit Pharmaceuticals Inc. has a 12 month low of $0.11 and a 12 month high of $22.00.
Analysts Set New Price Targets
Separately, Berenberg Bank raised Conduit Pharmaceuticals to a “strong-buy” rating in a research note on Friday, July 26th.
Get Our Latest Research Report on CDT
Conduit Pharmaceuticals Company Profile
Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Recommended Stories
- Five stocks we like better than Conduit Pharmaceuticals
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- What Are Dividends? Buy the Best Dividend Stocks
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Most Volatile Stocks, What Investors Need to Know
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Conduit Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conduit Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.